LivaNova PLC (LIVN) 10-Year Financial Performance & Capital Metrics

LIVN • • Industrial / General

HealthcareMedical DevicesCardiovascular DevicesStructural Heart & Valve Devices

AboutLivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.Show more

Revenue $1.25B +8.7%
EBITDA $180M +2458.0%
Net Income $63M +260.4%
EPS (Diluted) 1.16 +262.5%
Gross Margin 69.48% +3.9%
EBITDA Margin 14.38% +2270.0%
Operating Margin 10.3% +273.4%
Net Margin 5.04% +231.7%
ROE 4.87% +244.8%
ROIC 6.01% +288.7%
Debt/Equity 0.51 +2.3%
Interest Coverage 2.05 +275.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 81 (top 19%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y16.09%

5Y2.94%

3Y6.58%

TTM8.64%

Profit (Net Income) CAGR

10Y1.43%

5Y-

3Y-

TTM-1018.29%

EPS CAGR

10Y-5.3%

5Y-

3Y-

TTM-1052.38%

ROCE

10Y Avg-2.55%

5Y Avg-3.07%

3Y Avg-0.53%

Latest6.13%

Peer Comparison

Structural Heart & Valve Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LIVNLivaNova PLC	3.35B	61.33	52.87	8.66%	-16.12%	-18.79%	4.06%	0.51
ABTAbbott Laboratories	216.14B	124.30	16.27	4.59%	31.88%	27.26%	2.94%	0.32
EWEdwards Lifesciences Corporation	48.65B	83.84	12.03	8.57%	23.19%	13.37%	0.6%	0.07
AVRAnteris Technologies Global Corp.	184.98M	4.49	-1.19	-1.16%	-39.42%	-25.1%		0.02

Profit & Loss

	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	291.56M	1.21B	1.01B	1.11B	1.08B	934.24M	1.04B	1.02B	1.15B	1.25B
Revenue Growth %	0.03%	3.16%	-0.17%	0.09%	-0.02%	-0.14%	0.11%	-0.01%	0.13%	0.09%
Cost of Goods Sold+	27.31M	509.5M	360.7M	372.5M	360.37M	339.48M	329.37M	314.58M	382.3M	382.56M
COGS % of Revenue	0.09%	0.42%	0.36%	0.34%	0.33%	0.36%	0.32%	0.31%	0.33%	0.31%
Gross Profit+	264.25M	704.4M	651.6M	734.5M	723.8M	594.76M	705.99M	707.23M	771.25M	870.87M
Gross Margin %	0.91%	0.58%	0.64%	0.66%	0.67%	0.64%	0.68%	0.69%	0.67%	0.69%
Gross Profit Growth %	0.04%	1.67%	-0.07%	0.13%	-0.01%	-0.18%	0.19%	0%	0.09%	0.13%
Operating Expenses+	166.9M	637.2M	523.4M	648.2M	895.36M	868.66M	706.78M	783.98M	839.75M	741.82M
OpEx % of Revenue	0.57%	0.52%	0.52%	0.59%	0.83%	0.93%	0.68%	0.77%	0.73%	0.59%
Selling, General & Admin	123.62M	469.2M	380.6M	465M	0	0	471.9M	469.24M	518.13M	526.26M
SG&A % of Revenue	0.42%	0.39%	0.38%	0.42%	-	-	0.46%	0.46%	0.45%	0.42%
Research & Development	43.28M	122.5M	109.7M	146M	197.15M	152.9M	183.41M	155.81M	193.82M	182.51M
R&D % of Revenue	0.15%	0.1%	0.11%	0.13%	0.18%	0.16%	0.18%	0.15%	0.17%	0.15%
Other Operating Expenses	642.36K	45.51M	33.14M	37.19M	698.21M	715.76M	51.46M	158.93M	127.8M	33.04M
Operating Income+	88.65M	-27.6M	95.7M	-248.1M	-171.55M	-273.9M	-784K	-76.75M	-68.5M	129.05M
Operating Margin %	0.3%	-0.02%	0.09%	-0.22%	-0.16%	-0.29%	-0%	-0.08%	-0.06%	0.1%
Operating Income Growth %	0.11%	-1.31%	4.47%	-3.59%	0.31%	-0.6%	1%	-96.9%	0.11%	2.88%
EBITDA+	95.91M	35.96M	165.9M	-178.16M	-100.86M	-206.56M	67.2M	-18.96M	-7.64M	180.19M
EBITDA Margin %	0.33%	0.03%	0.16%	-0.16%	-0.09%	-0.22%	0.06%	-0.02%	-0.01%	0.14%
EBITDA Growth %	0.12%	-0.63%	3.61%	-2.07%	0.43%	-1.05%	1.33%	-1.28%	0.6%	24.58%
D&A (Non-Cash Add-back)	7.25M	63.56M	70.2M	69.94M	70.69M	67.34M	67.99M	57.8M	60.86M	51.14M
EBIT	-56.66M	35.82M	128.94M	-237.62M	48.49M	-60.99M	-74.32M	-26.89M	-22.37M	151.38M
Net Interest Income+	0	-8.92M	-6.48M	-8.98M	-14.29M	-40.71M	-49.72M	-43.55M	-36.84M	-32.99M
Interest Income	0	1.7M	1.32M	847K	803K	131K	435K	4.7M	22.01M	30.07M
Interest Expense	162.89K	10.62M	7.8M	9.82M	15.09M	40.84M	50.15M	48.25M	58.85M	63.07M
Other Income/Expense	-130.98M	-66.45M	24.65M	625K	43.92M	-74.39M	-123.84M	1.56M	-12.83M	-40.74M
Pretax Income+	89.29M	-33M	121.1M	-247.4M	-127.63M	-348.29M	-124.62M	-75.19M	-81.33M	88.31M
Pretax Margin %	0.31%	-0.03%	0.12%	-0.22%	-0.12%	-0.37%	-0.12%	-0.07%	-0.07%	0.07%
Income Tax+	31.45M	7.1M	50M	-69.6M	30.37M	-960K	11.2M	11.05M	-98.88M	25.06M
Effective Tax Rate %	0.65%	1.9%	-0.21%	0.77%	1.24%	1%	1.09%	1.15%	-0.22%	0.72%
Net Income+	57.85M	-62.8M	-25.1M	-189.4M	-157.64M	-348.82M	-135.82M	-86.25M	17.55M	63.23M
Net Margin %	0.2%	-0.05%	-0.02%	-0.17%	-0.15%	-0.37%	-0.13%	-0.08%	0.02%	0.05%
Net Income Growth %	0.05%	-2.09%	0.6%	-6.55%	0.17%	-1.21%	0.61%	0.36%	1.2%	2.6%
Net Income (Continuing)	-22.08M	20.55M	71.18M	-177.82M	-158M	-347.33M	-135.82M	-86.25M	17.55M	63.25M
Discontinued Operations	-22.34M	-64.66M	-79.55M	0	365K	-1.49M	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	2.17	-1.28	-0.52	-3.91	-3.22	-7.06	-2.68	-1.61	0.32	1.16
EPS Growth %	0.09%	-1.59%	0.59%	-6.52%	0.18%	-1.19%	0.62%	0.4%	1.2%	2.63%
EPS (Basic)	2.19	-1.29	-0.52	-3.91	-3.22	-7.06	-2.68	-1.61	0.33	1.17
Diluted Shares Outstanding	26.63M	48.9M	48.5M	48.5M	48.35M	48.59M	50.63M	53.5M	54.21M	54.57M
Basic Shares Outstanding	26.39M	48.86M	48.2M	48.5M	48.35M	48.59M	50.63M	53.5M	53.9M	54.24M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	673.41M	620.1M	869.9M	533.3M	549.44M	708.04M	679.18M	886.14M	988.16M	1.13B
Cash & Short-Term Investments	119.61M	39.8M	93.6M	47.2M	61.14M	252.83M	207.99M	214.17M	266.5M	428.86M
Cash Only	112.61M	39.8M	93.6M	47.2M	61.14M	252.83M	207.99M	214.17M	266.5M	428.86M
Short-Term Investments	7M	0	0	0	0	0	0	0	0	0
Accounts Receivable	272.35M	213.26M	286.21M	256.1M	258.37M	185.16M	222.97M	214.82M	215.07M	223.7M
Days Sales Outstanding	340.96	64.12	103.2	84.44	86.98	72.34	78.61	76.74	68.05	65.14
Inventory	212.45M	183.5M	144.5M	153.5M	164.15M	115.28M	105.84M	129.38M	147.89M	147.57M
Days Inventory Outstanding	2.84K	131.46	146.22	150.41	166.27	123.95	117.29	150.12	141.2	140.79
Other Current Assets	26.58M	367.39M	265.24M	836K	28M	94.53M	104.75M	296.06M	311.37M	327.06M
Total Non-Current Assets+	1.89B	1.72B	1.63B	2.02B	1.86B	1.69B	1.52B	1.41B	1.44B	1.38B
Property, Plant & Equipment	244.59M	223.8M	192.4M	191.4M	235.73M	214.33M	190.67M	183.02M	205.03M	217.1M
Fixed Asset Turnover	1.19x	5.42x	5.26x	5.78x	4.60x	4.36x	5.43x	5.58x	5.63x	5.77x
Goodwill	745.36M	691.7M	784.2M	956.8M	915.79M	922.32M	899.52M	768.79M	782.94M	750.01M
Intangible Assets	658.94M	609.2M	535.4M	770.4M	607.55M	437.64M	399.68M	368.56M	261.18M	237.29M
Long-Term Investments	77.49M	61.1M	34.5M	24.8M	27.26M	103.4M	16.6M	16.27M	22.84M	25.08M
Other Non-Current Assets	5.45M	130.7M	76M	4.8M	7.36M	11.25M	13.1M	70.62M	50.56M	149.72M
Total Assets+	2.56B	2.34B	2.5B	2.55B	2.41B	2.4B	2.2B	2.29B	2.43B	2.51B
Asset Turnover	0.11x	0.52x	0.40x	0.43x	0.45x	0.39x	0.47x	0.45x	0.47x	0.50x
Asset Growth %	7.7%	-0.08%	0.07%	0.02%	-0.05%	-0%	-0.08%	0.04%	0.06%	0.03%
Total Current Liabilities+	359.12M	316.8M	406M	496.7M	512.55M	309.05M	696.97M	297.4M	334.98M	392.13M
Accounts Payable	109.59M	71.93M	85.92M	76.73M	85.89M	73.67M	68M	74.31M	80.84M	69.73M
Days Payables Outstanding	1.46K	51.53	86.94	75.19	87	79.21	75.36	86.22	77.19	66.52
Short-Term Debt	82.51M	47.65M	84.03M	28.79M	88.51M	24.62M	229.67M	23.43M	18.11M	78M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	86.29M	154.29M	154.12M	286.14M	255.02M	135.49M	297.75M	109.23M	98.97M	51.2M
Current Ratio	1.88x	1.96x	2.14x	1.07x	1.07x	2.29x	0.97x	2.98x	2.95x	2.87x
Quick Ratio	1.28x	1.38x	1.79x	0.76x	0.75x	1.92x	0.82x	2.54x	2.51x	2.50x
Cash Conversion Cycle	1.72K	144.05	162.48	159.66	166.25	117.08	120.54	140.63	132.06	139.41
Total Non-Current Liabilities+	388.16M	318.9M	282.6M	549.3M	515.53M	981.64M	209.34M	789.75M	816.95M	794.01M
Long-Term Debt	91.79M	75.22M	61.96M	139.54M	260.33M	642.3M	9.85M	518.07M	568.54M	549.62M
Capital Lease Obligations	2.51M	0	0	0	46.03M	42.22M	35.92M	29.55M	45.39M	40.1M
Deferred Tax Liabilities	235.48M	172.5M	123.3M	68.2M	32.22M	7.09M	7.73M	8.52M	11.57M	10.91M
Other Non-Current Liabilities	54.45M	54.45M	97.26M	341.49M	176.95M	290.04M	155.84M	233.62M	191.45M	193.36M
Total Liabilities	747.28M	635.7M	688.6M	1.05B	1.03B	1.29B	906.31M	1.09B	1.15B	1.19B
Total Debt+	176.82M	122.9M	146M	168.3M	394.86M	709.14M	286.7M	580.43M	640.4M	676.77M
Net Debt	64.2M	83.1M	52.4M	121.1M	333.73M	456.31M	78.71M	366.26M	373.9M	247.91M
Debt / Equity	0.10x	0.07x	0.08x	0.11x	0.29x	0.64x	0.22x	0.48x	0.50x	0.51x
Debt / EBITDA	1.84x	3.42x	0.88x	-	-	-	4.27x	-	-	3.76x
Net Debt / EBITDA	0.67x	2.31x	0.32x	-	-	-	1.17x	-	-	1.38x
Interest Coverage	544.25x	-2.60x	12.27x	-25.25x	-11.37x	-6.71x	-0.02x	-1.59x	-1.16x	2.05x
Total Equity+	1.81B	1.71B	1.82B	1.5B	1.38B	1.11B	1.29B	1.21B	1.28B	1.32B
Equity Growth %	5.99%	-0.06%	0.06%	-0.17%	-0.08%	-0.2%	0.17%	-0.07%	0.06%	0.03%
Book Value per Share	68.03	34.91	37.43	31.01	28.62	22.83	25.57	22.57	23.57	24.19
Total Shareholders' Equity	1.81B	1.71B	1.82B	1.5B	1.38B	1.11B	1.29B	1.21B	1.28B	1.32B
Common Stock	75.44M	74.58M	74.75M	76.14M	76.26M	76.3M	82.3M	82.42M	82.53M	83.16M
Retained Earnings	48.21M	-14.57M	-39.66M	-251.58M	-406.75M	-761.97M	-897.78M	-984.03M	-966.48M	-903.25M
Treasury Stock	0	-4.5M	-133K	-1.46M	-1.26M	-1.03M	-650K	-375K	-55K	-136K
Accumulated OCI	-54.23M	-68.49M	45.31M	-24.48M	-19.39M	27.81M	-7.18M	-48.12M	-27.88M	-80.17M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Apr 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	79.68M	90.2M	91.3M	120.5M	-91.14M	-79.4M	102.54M	69.9M	74.91M	183.04M
Operating CF Margin %	0.27%	0.07%	0.09%	0.11%	-0.08%	-0.08%	0.1%	0.07%	0.06%	0.15%
Operating CF Growth %	0.47%	0.13%	0.01%	0.32%	-1.76%	0.13%	2.29%	-0.32%	0.07%	1.44%
Net Income	57.85M	-62.8M	-25.1M	-189.4M	-157.64M	-345M	-135.82M	-86.2M	17.55M	63.23M
Depreciation & Amortization	7.25M	85.4M	83M	69.9M	82.99M	81.3M	67.99M	57.8M	60.86M	51.14M
Stock-Based Compensation	46.07M	19.6M	19.1M	26.9M	32.55M	35.09M	40.56M	44.81M	36.35M	33.93M
Deferred Taxes	9.4M	-26.7M	-9.3M	-95.1M	-26.5M	37.3M	2.85M	1.4M	-114.43M	6.79M
Other Non-Cash Items	-433.89K	95.5M	112.6M	303.4M	39.79M	222.9M	97.74M	83.8M	109.21M	26.63M
Working Capital Changes	-6.33M	-20.8M	-89M	4.8M	-62.34M	-111M	29.22M	-31.7M	-34.62M	1.31M
Change in Receivables	-2.65M	-16.4M	-48.9M	21.2M	-5.32M	58.8M	-15.74M	-4.8M	-28.86M	11.1M
Change in Inventory	-7.11M	26.7M	7.2M	-10.6M	-7.92M	1.4M	4.48M	-25.7M	-28.48M	-6.8M
Change in Payables	0	1.6M	-41.1M	7.2M	-38.58M	-900K	12.99M	-3.5M	19.19M	-14.5M
Cash from Investing+	-9.77M	-38.2M	-52.9M	-120.6M	-41.29M	-41.8M	36.9M	-38.4M	-40.33M	-48.16M
Capital Expenditures	-6.69M	-37.2M	-34.1M	-38M	-24.69M	-35M	-25.48M	-26.5M	-34.98M	-47.11M
CapEx % of Revenue	0.02%	0.03%	0.03%	0.03%	0.02%	0.04%	0.02%	0.03%	0.03%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	12.5M	3.04M	-1.5M	14.2M	-3.35M	-1.9M	1.73M	-88K	1.15M	89K
Cash from Financing+	-48.26M	-124.3M	11.3M	-42.3M	146.58M	310.8M	-181.48M	280.1M	21.48M	18.55M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	13.75M	-15.69M	3.69M	-9.73M	-19.3M	-90.69M	-16.19M	4.79M	2.58M	-60.98M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	72.99M	53M	57.2M	82.5M	-115.83M	-114.4M	77.07M	43.4M	39.93M	135.93M
FCF Margin %	0.25%	0.04%	0.06%	0.07%	-0.11%	-0.12%	0.07%	0.04%	0.03%	0.11%
FCF Growth %	1.08%	-0.27%	0.08%	0.44%	-2.4%	0.01%	1.67%	-0.44%	-0.08%	2.4%
FCF per Share	2.74	1.08	1.18	1.70	-2.40	-2.35	1.52	0.81	0.74	2.49
FCF Conversion (FCF/Net Income)	1.38x	-1.44x	-3.64x	-0.64x	0.58x	0.23x	-0.76x	-0.81x	4.27x	2.89x
Interest Paid	0	7.37M	7.51M	9.28M	15.83M	28.57M	32.57M	19.04M	0	38.89M
Taxes Paid	0	47.81M	38.97M	26.39M	2.01M	7.49M	0	1.22M	0	15.91M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	5.59%	-3.57%	-1.43%	-11.41%	-10.92%	-27.98%	-11.3%	-6.89%	1.41%	4.87%
Return on Invested Capital (ROIC)	6.55%	-1.13%	3.92%	-10.66%	-7.7%	-12.51%	-0.04%	-3.91%	-3.19%	6.01%
Gross Margin	90.63%	58.03%	64.37%	66.35%	66.76%	63.66%	68.19%	69.21%	66.86%	69.48%
Net Margin	19.84%	-5.17%	-2.48%	-17.11%	-14.54%	-37.34%	-13.12%	-8.44%	1.52%	5.04%
Debt / Equity	0.10x	0.07x	0.08x	0.11x	0.29x	0.64x	0.22x	0.48x	0.50x	0.51x
Interest Coverage	544.25x	-2.60x	12.27x	-25.25x	-11.37x	-6.71x	-0.02x	-1.59x	-1.16x	2.05x
FCF Conversion	1.38x	-1.44x	-3.64x	-0.64x	0.58x	0.23x	-0.76x	-0.81x	4.27x	2.89x
Revenue Growth	3.38%	316.35%	-16.61%	9.35%	-2.06%	-13.83%	10.82%	-1.31%	12.89%	8.66%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Cardiopulmonary	-	-	-	-	-	482.98M	500.31M	588.98M	683.51M
Cardiopulmonary Growth	-	-	-	-	-	-	3.59%	17.72%	16.05%
Neuromodulation	-	-	-	424.55M	354.44M	456.17M	476.99M	519.71M	554.22M
Neuromodulation Growth	-	-	-	-	-16.51%	28.70%	4.56%	8.96%	6.64%
Advanced Circulatory Support	-	-	-	-	-	55.46M	39.3M	40.32M	-
Advanced Circulatory Support Growth	-	-	-	-	-	-	-29.14%	2.60%	-
Cardiovascular	-	-	-	656.65M	577.08M	-	-	-	-
Cardiovascular Growth	-	-	-	-	-12.12%	-	-	-	-
Cardiac Surgery	611.72M	-	681.83M	-	-	-	-	-	-
Cardiac Surgery Growth	-	-	-	-	-	-	-	-	-
Neuromodulation	351.41M	-	422.99M	-	-	-	-	-	-
Neuromodulation Growth	-	-	-	-	-	-	-	-	-
Cardiac Rhythm Management	249.07M	-	-	-	-	-	-	-	-
Cardiac Rhythm Management Growth	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	490.51M	494.72M	-	546.48M	468.63M	571.3M	571.56M	635.04M	695.08M
UNITED STATES Growth	-	0.86%	-	-	-14.25%	21.91%	0.05%	11.11%	9.45%
Locations Excluding The United States And Europe	-	-	-	-	272.24M	262.54M	271.44M	303.71M	338.32M
Locations Excluding The United States And Europe Growth	-	-	-	-	-	-3.56%	3.39%	11.89%	11.40%
Europe	402.07M	210.47M	-	223.18M	193.37M	201.53M	178.8M	214.79M	220.03M
Europe Growth	-	-47.65%	-	-	-13.36%	4.22%	-11.28%	20.13%	2.44%
Rest Of World	-	-	2.15M	314.5M	-	-	-	-	-
Rest Of World Growth	-	-	-	14555.31%	-	-	-	-	-
Non-U.S. and Europe	321.35M	307.08M	-	-	-	-	-	-	-
Non-U.S. and Europe Growth	-	-4.44%	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

LivaNova PLC (LIVN) has a price-to-earnings (P/E) ratio of 52.9x. This suggests investors expect higher future growth.

Growth & Financials

LivaNova PLC (LIVN) reported $1.35B in revenue for fiscal year 2024. This represents a 608% increase from $190.5M in 2011.

LivaNova PLC (LIVN) grew revenue by 8.7% over the past year. This is steady growth.

LivaNova PLC (LIVN) reported a net loss of $217.5M for fiscal year 2024.

Dividend & Returns

LivaNova PLC (LIVN) has a return on equity (ROE) of 4.9%. This is below average, suggesting room for improvement.

LivaNova PLC (LIVN) generated $191.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...